Lectures

• 

  1. Snake Oil Origins

  In our introductory lecture, Gerald Posner uncovers the hidden origins of the pharmaceutical industry, from unregulated 19th-century “snake oil” cures to the rise of giants like Pfizer and Merck—companies that once sold addictive substances like morphine, cocaine, and heroin as miracle treatments. The discussion explores how profit-first thinking, aggressive marketing, and public misinformation shaped the industry, and how early regulations like the 1906 Pure Food and Drug Act were weakened by industry lobbying—setting patterns that still influence the pharmaceutical industry today.
• 

  2. Post-War Drug Boom

  In lecture two, we witness how World War II transformed the pharmaceutical industry through the Penicillin Project, a model of government-academia-industry collaboration that launched modern Big Pharma. Gerald Posner explains how wartime urgency drove massive funding and coordination between researchers and companies, enabling large-scale antibiotic production and paving the way for American firms to dominate global markets. We also see how the postwar boom fueled profits, aggressive marketing, and a shift from cures to chronic treatments—while overuse sparked antibiotic resistance—shaping an industry model that continues to drive modern pharma.
• 

  3. Selling Sickness

  In lecture three, we take a deeper dive into the pharmaceutical industry’s shift from science-driven ideals to marketing dominance, highlighting how Arthur Sackler revolutionized promotion in the 1950s and 1960s. We contrast his tactics with the public-minded ethos of George Merck and Jonas Salk, who prioritized patient welfare over profit. By introducing sales reps, ghostwritten research, and targeted ads, Sackler helped create a system that fueled “me-too” drugs and expanded disease definitions. This approach built a marketing machine that outpaced regulation and fundamentally reshaped relationships between pharmaceutical companies, doctors, and patients.
• 

  4. Regulation Revolution

  In lecture four, we learn about the pivotal period of pharmaceutical regulation in the 1950s-60s, focusing on Senator Estes Kefauver's groundbreaking investigation into drug industry practices. We examine how safety failures, deceptive marketing, and the thalidomide crisis led to the landmark 1962 Kefauver-Harris Amendments, which for the first time required pharmaceutical companies to prove both safety and efficacy before drug approval, fundamentally reshaping pharmaceutical oversight in America.
• 

  5. Mother's Little Helper

  In lecture five, we investigate how pharmaceutical companies targeted women from the 1950s onward by medicalizing anxiety, stress, and normal life transitions like menopause. It traces the path from early anxiolytics to amphetamines, hormone therapies, and ultimately opioids, showing how everyday emotions were reframed as conditions needing medication. We see how Arthur Sackler’s marketing blueprint promoted pills as safe, simple solutions while downplaying addiction risks, creating patterns of dependency that fueled massive profits and lasting harm. Gerald Posner reveals how these gendered strategies helped shape the modern opioid crisis, and concludes with guidance on recognizing these manipulative tactics as patients.
• 

  6. Pills, Power & Political Capture

  In lecture six, we study how the pharmaceutical industry has maintained dominance through political influence, regulatory capture, and sophisticated marketing. We examine how companies have shaped legislation to protect profits, from Medicare’s non-interference clause to modern drug pricing rules, while exploiting loopholes such as patent evergreening, pay-for-delay deals, and off-label prescribing. Case studies including minoxidil (Rogaine), sildenafil (Viagra), and gabapentin show how drugs are repurposed and expanded into massive markets. The discussion reveals a system that prioritizes profit over patient safety while preserving the appearance of innovation and public benefit.
• 

  7. Price of Monopoly & Orphan Drugs

  In lecture seven, we consider how pharmaceutical companies have transformed the 1983 Orphan Drug Act—originally meant to encourage treatments for rare diseases—into a highly profitable system through legal and regulatory loopholes. We examine cases including AZT during the AIDS crisis, Botox’s shift from eye spasms to cosmetics, and modern gene therapies costing millions per patient. We see how pharmaceutical companies leverage strategies such as indication stacking, off-label expansion, and tax-supported exclusivity to maximize profits from small patient populations. The lecture also highlights how pharmacy benefit managers (PBMs) add opacity and inflate costs through rebate systems, revealing a model where taxpayer-supported innovation often becomes extreme private profit while patients bear the financial burden.
• 

  8. Pandemic Profits

  In our eighth and final lecture, we explore how the COVID-19 pandemic was turned into a major profit opportunity. We examine how companies like Pfizer and Moderna benefited from public-private partnerships that socialized research and development risk while privatizing profits. The companies generated hundreds of billions in revenue and received billions in taxpayer funding, yet pricing transparency and accountability remained limited despite the scale of public investment. Gerald Posner concludes by emphasizing the importance of becoming informed healthcare consumers who maintain healthy skepticism about pharmaceutical marketing and financial incentives, while recognizing that modern medicine does provide genuine benefits when approached with proper awareness of the profit-driven system behind it.